Helal Mariam W, Faried Mohanad M, Salah Sohaila Mohammed, Ashraf Mazen, Nasser Nada, Shawky Yasser, Hamdy Sara, Amir Azza El, Nabil Wajeet, El-Husseini Dalia M
Biotechnology Department, Faculty of Science, Cairo University, Giza, Egypt.
Zoology Department, Faculty of Science, Cairo University, Giza, Egypt.
Appl Biochem Biotechnol. 2025 Mar;197(3):1678-1695. doi: 10.1007/s12010-024-05091-2. Epub 2024 Nov 27.
Breast cancer remains a challenging health issue, demanding innovative treatment approaches that maximize efficacy while minimizing damage to healthy cells. Targeted therapy offers a promising strategy tailored to the unique characteristics of breast cancer tumors. Gold nanoparticles have been studied in the context of their therapeutic potential towards cancer treatment showing great success. Recently, aptamers were also investigated for their targeting efficiency towards specific receptors allowing their use in targeting delivery systems. In this study, computational analysis was used to confirm the strong binding between AS1411 aptamer and the nucleolin receptor extensively present on the surface of breast cancer cells, highlighting the aptamer's potential for specific targeting. Furthermore, we investigated and compared the use of AS1411 aptamer-conjugated chemically synthesized (GNPs) and flaxseed-green-synthesized (Fs-GNPs) gold nanoparticles as targeting therapeutic systems for breast cancer cells. Our results showed successful conjugation of the AS1411 aptamer with both, the GNPs and Fs-GNPs. Characterization of the nanoparticles and their conjugates validates their size, charge, and morphology, affirming the success of the conjugation process. Cytotoxicity assessments using the MTT assay demonstrated the effectiveness of the conjugates against breast cancer cells, with the AS1411-Fs-GNPs conjugate exhibiting higher inhibitory efficacy, featuring an IC value of 11.13 µg/ml. In contrast, they showed minimal effect on normal cells, emphasizing the selectivity and potential safety of these therapies. To our knowledge, this is the first report of conjugating AS1411 aptamer to green-synthesized gold nanoparticles and its use as a targeting therapeutic system.
乳腺癌仍然是一个具有挑战性的健康问题,需要创新的治疗方法,在最大限度提高疗效的同时,将对健康细胞的损害降至最低。靶向治疗提供了一种针对乳腺癌肿瘤独特特征量身定制的有前景的策略。金纳米颗粒因其在癌症治疗方面的治疗潜力而得到研究,并取得了巨大成功。最近,适配体也因其对特定受体的靶向效率而受到研究,使其可用于靶向递送系统。在本研究中,通过计算分析证实了AS1411适配体与广泛存在于乳腺癌细胞表面的核仁素受体之间的强结合,突出了该适配体的特异性靶向潜力。此外,我们研究并比较了将AS1411适配体与化学合成的金纳米颗粒(GNPs)和亚麻籽绿色合成的金纳米颗粒(Fs-GNPs)共轭作为乳腺癌细胞靶向治疗系统的应用。我们的结果表明,AS1411适配体与GNPs和Fs-GNPs均成功共轭。对纳米颗粒及其共轭物的表征验证了它们的大小、电荷和形态,证实了共轭过程的成功。使用MTT法进行的细胞毒性评估证明了共轭物对乳腺癌细胞的有效性,AS1411-Fs-GNPs共轭物表现出更高的抑制效力,IC值为11.13 µg/ml。相比之下,它们对正常细胞的影响极小,强调了这些疗法的选择性和潜在安全性。据我们所知,这是关于将AS1411适配体与绿色合成金纳米颗粒共轭并将其用作靶向治疗系统的首次报道。